MBRX Key Statistics, Chart & Performance
The current stock price of MBRX is 3.98 USD. In the past month the price decreased by -17.6%. In the past year, price decreased by -90.29%.
MBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About MBRX
Company Profile
Moleculin Biotech Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Company Info
MOLECULIN BIOTECH INC
5300 Memorial Dr Ste 950
Houston TEXAS 77007 US
CEO: Walter V. Klemp
Employees: 17
Phone: 17133005160
MOLECULIN BIOTECH INC / MBRX FAQ
Can you describe the business of MOLECULIN BIOTECH INC?
Moleculin Biotech Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
What is the current price of MBRX stock?
The current stock price of MBRX is 3.98 USD. The price decreased by -3.16% in the last trading session.
Does MBRX stock pay dividends?
MBRX does not pay a dividend.
What is the ChartMill rating of MOLECULIN BIOTECH INC stock?
MBRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is MOLECULIN BIOTECH INC worth?
MOLECULIN BIOTECH INC (MBRX) has a market capitalization of 8.24M USD. This makes MBRX a Nano Cap stock.
When does MOLECULIN BIOTECH INC (MBRX) report earnings?
MOLECULIN BIOTECH INC (MBRX) will report earnings on 2026-03-19, after the market close.
MBRX Technical Analysis
MBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MBRX. MBRX has a bad profitability rating. Also its financial health evaluation is rather negative.
MBRX Financial Highlights
Over the last trailing twelve months MBRX reported a non-GAAP Earnings per Share(EPS) of -55.82. The EPS increased by 80.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -203.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MBRX Forecast & Estimates
9 analysts have analysed MBRX and the average price target is 52.02 USD. This implies a price increase of 1207.04% is expected in the next year compared to the current price of 3.98.